HSPG expression in non alcohol steatosis hepatitis in type II diabetes

HSPG expression in non alcohol steatosis hepatitis in type II diabetes - HSPG in NASH

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33031

Enrollment

Registered

2009-11-23

Start date

2009-09-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes glucose intolerance

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Caucasian males aged between 18 and 60 years of age with either type 2 diabetes mellitus or FHBL AND presence of ultrasound confirmed NASH in conjunction with elevated liverfunction tests. Subjects with stable hereditary hemochromatosis (treated with venesection therapy) who need a liverbiopsy for staging of disease will be used as controls

Exclusion criteria

Exclusion criteria: Use of medication which is known to influence cholesterol metabolism, an active malignancy or presence of a contraindication for liver biopsy

Design outcomes

Primary

Measure	Time frame
HSPG expression will be altered (HS synthesizing enzymes: EXT/NDST/OST decreased and HS degrading enzymes: SULF2 and heparinase increased) in DM2	—

Secondary

Measure	Time frame
Second Objective: HSPG expression is linearly correlated with increased levels of triglyceride rich lipoproteins in non-fasting blood samples Third objective: HSPG expression is inversely correlated with insulin resistance	—

Countries

Netherlands

Outcome results